SG11201909837YA - Methods for treating lung disorders - Google Patents

Methods for treating lung disorders

Info

Publication number
SG11201909837YA
SG11201909837YA SG11201909837YA SG11201909837YA SG 11201909837Y A SG11201909837Y A SG 11201909837YA SG 11201909837Y A SG11201909837Y A SG 11201909837YA SG 11201909837Y A SG11201909837Y A SG 11201909837YA
Authority
SG
Singapore
Prior art keywords
crititech
lawrence
road
international
pct
Prior art date
Application number
Inventor
Michael Baltezor
Matthew Mcclorey
William Johnston
Gere Dizerega
James Verco
Original Assignee
Crititech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crititech Inc filed Critical Crititech Inc
Publication of SG11201909837YA publication Critical patent/SG11201909837YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 December 2018 (20.12.2018) WIPO I PCT omit ° oIo0101110l Oil Imo En oimIE (10) International Publication Number WO 2018/231908 Al (51) International Patent Classification: A61K 9/10 (2006.01) A61P 35/00 (2006.01) A61K 9/14 (2006.01) A61P 11/00 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). A61K 47/02 (2006.01) A61K 31/337 (2006.01) A61K 47/26 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/US2018/037219 (22) International Filing Date: 13 June 2018 (13.06.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/519,257 14 June 2017 (14.06.2017) US 62/628,582 09 February 2018 (09.02.2018) US 62/653,942 06 April 2018 (06.04.2018) US 62/678,387 31 May 2018 (31.05.2018) US (71) Applicant: CRITITECH, INC. [US/US]; 1849 E. 1450 Road, Lawrence, KS 66044 (US). = (72) Inventors: BALTEZOR, Michael; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). MC- CLOREY, Matthew; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). JOHNSTON, William; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). DIZEREGA, Gere, S.; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). VERCO, James; c/ o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). (74) Agent: BIELSKY, Isadora, F.; Mcdonnell Boehnen Hul- bert & Berghoff LLP, 300 South Wacker Drive, Chicago, IL 60606 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 O (54) Title: METHODS FOR TREATING LUNG DISORDERS \" (57) : Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary admin- C istration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.
SG11201909837Y 2017-06-14 2018-06-13 Methods for treating lung disorders SG11201909837YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762519257P 2017-06-14 2017-06-14
US201862628582P 2018-02-09 2018-02-09
US201862653942P 2018-04-06 2018-04-06
US201862678387P 2018-05-31 2018-05-31
PCT/US2018/037219 WO2018231908A1 (en) 2017-06-14 2018-06-13 Methods for treating lung disorders

Publications (1)

Publication Number Publication Date
SG11201909837YA true SG11201909837YA (en) 2019-11-28

Family

ID=62779154

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909837Y SG11201909837YA (en) 2017-06-14 2018-06-13 Methods for treating lung disorders
SG10201913400QA SG10201913400QA (en) 2017-06-14 2018-06-13 Methods for treating lung disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913400QA SG10201913400QA (en) 2017-06-14 2018-06-13 Methods for treating lung disorders

Country Status (10)

Country Link
US (3) US10398646B2 (en)
EP (1) EP3615004A1 (en)
JP (2) JP6840869B2 (en)
KR (2) KR20210118468A (en)
CN (2) CN115919815A (en)
AU (2) AU2018284247B2 (en)
BR (1) BR112019022720A2 (en)
CA (1) CA3063436A1 (en)
SG (2) SG11201909837YA (en)
WO (1) WO2018231908A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6921759B2 (en) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド Collection device and usage
AU2017246316B2 (en) 2016-04-04 2022-09-29 Crititech, Inc. Methods for solid tumor treatment
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CA3063436A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
BR112020021437A2 (en) * 2018-05-31 2021-01-19 Crititech, Inc. METHODS TO ISOLATE TUMOR-SPECIFIC IMMUNE CELLS FROM A SUBJECT TO ADOPTIVE CELL THERAPY AND CANCER VACCINES
WO2019231499A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for treatment of cancer
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
EP0954283B1 (en) 1996-12-30 2007-03-21 Battelle Memorial Institute Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation
CN100462066C (en) 1997-06-27 2009-02-18 美国生物科学有限公司 Novel formulations of pharmacological agents, method for preparation thereof and method for use thereof
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP3418751B2 (en) 1998-01-22 2003-06-23 参天製薬株式会社 Fluorometholone suspension ophthalmic solution
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
WO2000030660A2 (en) 1998-11-25 2000-06-02 Universitätsklinikum Freiburg Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
CA2371836C (en) 1999-05-27 2006-01-31 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6616849B1 (en) 1999-08-25 2003-09-09 Shimadzu Corporation Method of and system for continuously processing liquid materials, and the product processed thereby
AU1374601A (en) 1999-11-12 2001-05-30 Angiotech International Ag Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
CN1167461C (en) 1999-12-04 2004-09-22 研究发展基金会 Carbon dioxide enhancement of inhalation therapy
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6562952B1 (en) 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US20020081339A1 (en) 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
US20020192280A1 (en) 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US7276190B2 (en) 2001-07-02 2007-10-02 Micro & Nano Materials Sagl Process for the production of micro and/or nano particles
AU2002323266B2 (en) * 2001-08-20 2008-04-24 Transave, Inc. Method for treating lung cancers
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
WO2003032906A2 (en) 2001-10-15 2003-04-24 Crititech, Inc. Delivery of poorly soluble drugs
US20030166509A1 (en) 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
EP1480691A4 (en) 2002-03-05 2007-11-28 Univ State Cleveland Agglomerated particles for aerosol drug delivery
DE60309300T3 (en) 2002-03-20 2011-02-24 Elan Pharma International Ltd. NANOPARTICLE COMPOSITIONS OF ANGIOGENIC INHIBITORS
AU2003226567A1 (en) 2002-04-25 2003-11-10 Nektar Therapeutics Uk Ltd Particulate materials
JP2005529127A (en) 2002-04-26 2005-09-29 テバ ファーマシューティカル インダストリーズ リミティド Microparticle pharmaceutical composition for intratumoral delivery
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CN1255394C (en) 2002-06-24 2006-05-10 成都思摩纳米技术有限公司 Process for the manufacture of pacilitaxel nano granule
KR100573289B1 (en) 2002-07-20 2006-04-24 대화제약 주식회사 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof
WO2004098570A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
KR100508518B1 (en) 2002-11-13 2005-08-17 한미약품 주식회사 Method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby
TR200502189T1 (en) 2002-12-09 2007-01-22 American Bioscience, Inc. Compositions and methods for the transfer of pharmacologically active substances.
US7455797B2 (en) 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
CA2520475C (en) 2003-04-03 2012-10-09 Jessie L.-S. Au Tumor-targeting drug-loaded particles
US20060147535A1 (en) 2003-04-16 2006-07-06 Poongunran Muthukumaran Methods for and compositions of anticancer medicaments
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
JP2007001865A (en) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd Fine particle enclosing fat-soluble medicine, method for producing the same and preparation containing the same
CA2542217C (en) 2003-10-15 2018-03-27 Medigene Ag Method of administering cationic liposomes comprising an active drug
WO2005042219A1 (en) 2003-10-24 2005-05-12 Ferro Corporation Method of forming particles
CA2544627A1 (en) * 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
GB0402963D0 (en) 2004-02-11 2004-03-17 Univ Nottingham Counter current mixing device for two different fluids
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
EP1818093B1 (en) 2004-10-29 2014-03-12 Nara Machinery Co., Ltd. Method of granulating fine particles
JP2008523151A (en) 2004-12-14 2008-07-03 トランセイブ， インク． Lipid particles containing physiologically active substances, methods for their preparation and use
ES2265262B1 (en) 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) PROCEDURE FOR OBTAINING MICRO- AND NANODISPERSE SYSTEMS.
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20080003322A (en) * 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 Nanoparticulate formulations of docetaxel and analogues thereof
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
CN101160116B (en) 2005-03-31 2011-12-07 利德斯公司 Method for treating prostate diseases based on local delivery of active substances
CN1923189A (en) 2005-08-30 2007-03-07 孔庆忠 Taxine kind anti-cancer slow release injection
CN101291658B (en) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2007065446A2 (en) 2005-12-11 2007-06-14 Scf Technologies A/S Production of nanosized materials
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
AR054215A1 (en) 2006-01-20 2007-06-13 Eriochem Sa A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT
CN101336899A (en) 2006-01-25 2009-01-07 济南帅华医药科技有限公司 Anticancer sustained-released injection containing taxane
DE602007005231D1 (en) 2006-03-14 2010-04-22 Lidds Ab BIORESORBABLE COMPOSITION WITH CONTROLLED RELEASE
KR20080105174A (en) 2006-04-03 2008-12-03 테바 파마슈티컬 인더스트리즈 리미티드 Drug microparticles
CN101460147A (en) * 2006-04-03 2009-06-17 特瓦制药工业有限公司 Drug microparticles
US7744923B2 (en) 2006-10-11 2010-06-29 Crititech, Inc. Method for precipitation of small medicament particles into use containers
EP2139470A4 (en) 2007-03-23 2010-07-28 Elan Pharma Int Ltd Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same
TWI405590B (en) 2007-04-06 2013-08-21 Activus Pharma Co Ltd Method of producing pulverized organic compound particle
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
CN101754747A (en) * 2007-06-05 2010-06-23 Paka肺部医药公司 Methods and compositions for delivery of medicaments to the lungs
WO2009006590A2 (en) 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Docetaxel process and polymorphs
CN101129338A (en) 2007-08-27 2008-02-27 四川大学 Minuteness anti-cancer medicine paclitaxel of novel technique supercritical fluid
AU2009222230A1 (en) 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
ES2467676T3 (en) 2008-09-19 2014-06-12 Activus Pharma Co., Ltd. Powder of a combined organic compound for medical use, method for producing the same and suspension thereof
EP3181123A1 (en) 2008-12-02 2017-06-21 Biocompatibles Uk Ltd. Pancreatic tumour treatment
PT104693B (en) 2009-07-27 2011-11-24 Univ Lisboa SEMI-SOLID LIPID NANOPARTICLES CONTAINING AN ANTINEOPLASTIC AGENT AND ITS PREPARATION PROCESS
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US8623329B1 (en) 2009-10-13 2014-01-07 Aerophase, Inc. Method for the treatment of lung tumors
CN102091062A (en) * 2009-12-11 2011-06-15 国家纳米技术与工程研究院 Method for treating lung cancer by sucking and administrating taxol
CN101829061A (en) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 Taxol nanoparticle composition and preparation method thereof
NZ708506A (en) 2010-06-02 2016-08-26 Abraxis Bioscience Llc Methods of treating bladder cancer
CA2811869A1 (en) 2010-09-21 2012-03-29 Cristal Delivery B.V. Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith
JP2014504260A (en) 2010-10-15 2014-02-20 グラクソ グループ リミテッド Aggregated nanoparticulate drug formulation, its manufacture and use
WO2012096995A2 (en) 2011-01-11 2012-07-19 Boston Scientific Scimed, Inc. Coated medical devices
KR20140022904A (en) 2011-04-20 2014-02-25 유니버시티 오브 시드니 A method for the treatment of a solid tumour
WO2013052158A2 (en) 2011-04-26 2013-04-11 William Marsh Rice University Targeted nanovectors and their use for treatment of brain tumors
EA201490047A1 (en) 2011-06-17 2014-08-29 Берг Ллк INHALATION PHARMACEUTICAL COMPOSITIONS
EP2723388B1 (en) 2011-06-27 2021-04-14 Cristal Delivery B.V. Controlled release system
FR2980683B1 (en) * 2011-09-30 2014-11-21 Univ Paris Curie DEVICE FOR GUIDING A MEDICAL INSTRUMENT INSERTED IN A NATURAL PATH OR AN ARTIFICIAL PATH OF A PATIENT
CN102488682A (en) 2011-11-22 2012-06-13 四川九章生物化工科技发展有限公司 New application of chlorogenic acid in cancer resisting
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
TW201408304A (en) 2012-08-31 2014-03-01 Cathay General Hospital A combined drug with anti-cancer drug and hormone to treat renal cell carcinoma and its method of fabrication
AU2013318338B2 (en) 2012-09-21 2017-05-25 Intensity Therapeutics, Inc Method of treating cancer
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
PL2961377T3 (en) 2013-02-28 2020-11-02 Pf Consumer Healthcare 1 Llc Enhanced stability of novel liquid compositions
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
US9925512B2 (en) 2013-03-14 2018-03-27 Crititech, Inc. Equipment assembly for and method of processing particles
WO2014155146A1 (en) 2013-03-28 2014-10-02 Bbs Nanotechnology Llc Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
US9301926B2 (en) 2013-04-10 2016-04-05 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
US10188738B2 (en) 2013-10-16 2019-01-29 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
HUE047699T2 (en) 2013-12-17 2020-05-28 Hoffmann La Roche Methods of treating cancers using pd-1 axis binding antagonists and taxanes
KR20230076867A (en) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 Combination therapy with neoantigen vaccine
WO2015103005A1 (en) 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
TWI601542B (en) 2014-04-18 2017-10-11 林信湧 Inhalation-type pharmaceutical composition for lung cancer and preparation method thereof
US20150342872A1 (en) * 2014-06-01 2015-12-03 Crititech, Inc. Use of Paclitaxel Particles
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
JP6921759B2 (en) * 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド Collection device and usage
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
DE202016006620U1 (en) 2015-10-28 2017-04-12 Qass Gmbh Devices for observing a magnetic field of a material volume
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2017246316B2 (en) 2016-04-04 2022-09-29 Crititech, Inc. Methods for solid tumor treatment
CN107281502B (en) 2016-04-05 2021-05-04 上海市肿瘤研究所 Composite developing temperature-sensitive gel suppository, preparation method and application thereof
WO2017178585A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102462041B1 (en) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Carrier for cancer treatment-PD-L1 binder composition
ES2955884T3 (en) 2017-03-15 2023-12-07 Dfb Soria Llc Topical therapy for the treatment of skin malignancies with taxane nanoparticles
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CA3063436A1 (en) * 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders

Also Published As

Publication number Publication date
AU2018284247A1 (en) 2019-11-07
RU2019134091A (en) 2021-07-14
US20180360748A1 (en) 2018-12-20
CN115919815A (en) 2023-04-07
US10398646B2 (en) 2019-09-03
JP6840869B2 (en) 2021-03-10
AU2020204217A1 (en) 2020-07-16
RU2019134091A3 (en) 2021-11-08
US10507181B2 (en) 2019-12-17
US20190314277A1 (en) 2019-10-17
EP3615004A1 (en) 2020-03-04
JP2021075571A (en) 2021-05-20
AU2020204217B2 (en) 2021-11-18
AU2018284247B2 (en) 2020-04-30
KR20210118468A (en) 2021-09-30
KR102303762B1 (en) 2021-09-23
US11160754B2 (en) 2021-11-02
JP2020523286A (en) 2020-08-06
SG10201913400QA (en) 2020-03-30
BR112019022720A2 (en) 2020-05-12
CA3063436A1 (en) 2018-12-20
CN110799176A (en) 2020-02-14
WO2018231908A1 (en) 2018-12-20
US20200060969A1 (en) 2020-02-27
KR20200015479A (en) 2020-02-12

Similar Documents

Publication Publication Date Title
SG11201909837YA (en) Methods for treating lung disorders
SG11201808125RA (en) Methods for solid tumor treatment
SG11201811432WA (en) Rna for cancer therapy
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201900028VA (en) Crispr/cas9-based compositions and methods for treating cancer
SG11201808990QA (en) Compositions for topical application of compounds
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201805645QA (en) Lsd1 inhibitors
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201803906PA (en) Control of cellular redox levels
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201808913WA (en) Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
SG11201909840TA (en) Treatment of epithelial cysts by intracystic injection of antineoplastic particles
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201804770QA (en) Method and arrangement for recovery of salt
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201809882XA (en) Pharmaceutical combinations for treating cancer